Alkermes (ALKS) Price Target Increased After Narcolepsy Drug Data
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowNeedham has raised the price target for Alkermes (ALKS) following positive data on its narcolepsy drug. The new target reflects optimism surrounding the drug's performance and its potential market impact. The stock's performance may see changes based on analysts' expectations, particularly in the context of treatment advancements for narcolepsy. Increased investor interest can affect trading volumes as news circulates about this pivotal milestone.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
